Advocacy intelligence hub — real-time data for patient organizations
University of California, San Francisco — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
VIMIZIM
BioMarin Pharmaceutical Inc.
VIMIZIM
(ELOSULFASE ALFA)Orphan drugstandardBioMarin Pharmaceutical Inc.
Debra Lounsbury
BioMarin Pharmaceutical
Shunji Tomatsu, MD PhD
Nemours Children's Care
Tippi MacKenzie, MD
University of California, San Francisco
📍 San Francisco, California
Celeste Decker, MD
BioMarin Pharmceutical Inc.
📍 CONCORD, NH
Ellen B Fung, PhD, PhD, RD
University of California, San Francisco
📍 OAKLAND, CA
Richard Curtis Rogers, MD
Greenwood Genetic Center